Physician profile
Jerald Giles
NPI 1447435490
$3,062.54
in general payments reported to CMS, 2019-2025
31 companies · $776 in 2025
The $776 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $328 · 2021: $252 · 2022: $532 · 2023: $588 · 2024: $396 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687 · Education: $73.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.77 |
| Education | $73.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $818.50 | 2019-2025 | Dupixent |
| Genzyme Corporation | $449.23 | 2019-2025 | |
| Optinose US, INC. | $240.14 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $197.59 | 2021-2023 | Cuvitru |
| Stryker Corporation | $191.63 | 2019-2025 | Scopis Ent |
| Medtronic, INC. | $173.80 | 2024-2025 | Propel |
| Glaxosmithkline, LLC. | $163.97 | 2021-2025 | Nucala |
| Smith+Nephew, INC. | $97.39 | 2020-2021 | |
| Kaleo, INC. | $83.14 | 2022 | |
| Inspire Medical Systems, INC. | $80.78 | 2023-2024 | Inspire |
| Merck Sharp & Dohme LLC | $65.73 | 2021-2025 | Keytruda |
| Blueprint Medicines Corporation | $64.24 | 2025 | Ayvakit |
| Alk-Abello, INC | $51.57 | 2019-2020 | |
| Cochlear Americas | $42.40 | 2020-2023 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Ethicon US, LLC | $39.05 | 2023-2025 | Mega Soft, Stratafix, Harmonic |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $32.86 | 2023 | Acclarent Aera |
| Intersect Ent, INC. | $25.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.88 | 2021 | |
| Olympus America INC. | $24.10 | 2024 | Connecting Tube |
| Novartis Pharmaceuticals Corporation | $22.67 | 2019 | |
| Integra Lifesciences Corporation | $22.65 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Ars Pharmaceuticals Operations, INC. | $21.81 | 2025 | Neffy |
| Csl Behring | $21.03 | 2022 | |
| Aerin Medical INC. | $20.13 | 2022 | |
| Cook Medical LLC | $17.04 | 2023 | Biodesign |
| Genentech USA, INC. | $16.75 | 2019 | |
| Cycle Pharmaceuticals INC | $15.69 | 2024 | Sajazir |
| Astrazeneca Pharmaceuticals LP | $14.78 | 2025 | Tezspire |
| Ibsa Pharma INC. | $12.11 | 2022 | |
| Tactile Systems Technology INC | $11.36 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$478,046.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerald Giles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.